Franchise opportunities compared
Mold Medics vs Prism Specialties
Reviewed figures from each brand's Franchise Disclosure Document (FDD), side by side. Each figure carries its FDD year and page. This is not a ranking or recommendation, and the two FDDs may cover different years and location groups.
Before you compare
- Both sets of figures come from 2026 FDDs.
- Item 19 figures cover the location groups each FDD names (Mold Medics: 4, Prism Specialties: 1). Different groups are not directly comparable.
| Disclosure |  Mold Medics |  Prism Specialties |
|---|---|---|
| Financial commitment | ||
| Estimated initial investment (Item 7) | $148,400 – $211,725 TOTAL 2026 FDD · Item 7 · PDF p. 17 · printed p. 9 | Not available No reviewed Item 7 total |
| Standard initial franchise fee (Item 5) | $49,500 Item 5 also lists waivers, discounts and refunds, including multi-territory discounts. 2026 FDD · Item 5 · PDF p. 9 · printed p. 1 | Not available No single standard fee identified |
| Royalty (Item 6) | 7% or $500–$1,500/mo min Base Royalty 2026 FDD · Item 6 · PDF p. 10 · printed p. 2 | 7% Royalty fee 2026 FDD · Item 6 · PDF p. 19 |
| Brand / advertising fund (Item 6) | 2% of percentage of gross sales Brand Fund Fee 2026 FDD · Item 6 · PDF p. 10 · printed p. 2 | 2% National marketing fund contribution — 2% 2026 FDD · Item 6 · PDF p. 19 |
| System scale & health | ||
| Total outlets (Item 20) | 18 Outlets at end of 2025 2026 FDD · Item 20 · PDF p. 42 · printed p. 34 | 15 Outlets at end of 2025 2026 FDD · Item 20 · PDF p. 68 |
| Net outlet change (Item 20) | +14 Calculated: 4 at end of 2023 → 18 at end of 2025 | +14 Calculated: 1 at end of 2023 → 15 at end of 2025 |
| Outlet exits (Item 20) | 0 Closures, terminations & non-renewals in 2025 · Calculated turnover 0.0% of outlets at start of year 2026 FDD · Item 20 · PDF p. 42 · printed p. 34 | Not available No complete exit records for a year |
| Franchising since (Item 1) | 2020 2026 FDD · Item 1 · PDF p. 9 | 2012 From a verified franchisor listing |
| Franchisor founded (Item 1) | 2019 2026 FDD · Item 1 · PDF p. 9 | Not available Not in reviewed records |
| Performance (Item 19) | ||
| Financial performance (Item 19), by location group | Franchised (3 locations) — adjusted operating results — 3 Mold Medics franchises, operating 9 territories, that reported Gross Sales an… $708,411 mean Gross Sales · 2026 FDD · Item 19 · PDF p. 40 · printed p. 32 Franchised (3 locations) — adjusted operating results — “3 Mold Medics franchises, operating 9 territories, that reported Gross Sales a… 66 percent other Gross Profit Margin · 2026 FDD · Item 19 · PDF p. 39 · printed p. 31 Franchised and company-owned locations — revenue $1,564,712 other System-Wide Gross Sales · 2026 FDD · Item 19 · PDF p. 41 · printed p. 33 +1 more groups in the full report | Locations counted not stated in the reviewed record $678,583 other gross sales, single service line · 2026 FDD · Item 19 · PDF p. 65 |
Item 19 groups are shown separately and never combined. Revenue or sales figures are not profit. Net outlet change and turnover are Franopolis calculations from the disclosed counts; turnover is a count-based rate, not a measure of owner earnings.
Mold Medics vs Prism Specialties: common questions
- How do Mold Medics and Prism Specialties royalties compare?
- Mold Medics: 7% or $500–$1,500/mo min (2026 FDD · Item 6 · PDF p. 10 · printed p. 2); Prism Specialties: 7% (2026 FDD · Item 6 · PDF p. 19). Royalties as disclosed in Item 6; other recurring fees are listed separately.
- Which has more locations, Mold Medics or Prism Specialties?
- Mold Medics: 18 (2026 FDD · Item 20 · PDF p. 42 · printed p. 34); Prism Specialties: 15 (2026 FDD · Item 20 · PDF p. 68). Total outlets from Item 20. Outlet counts do not indicate territory availability or franchisee results.
- Do Mold Medics and Prism Specialties disclose financial performance (Item 19)?
- Mold Medics has reviewed Item 19 figures for 4 location groups; Prism Specialties has reviewed Item 19 figures for 1 location group. Different location groups are not directly comparable, and revenue is not profit.
Answers restate the reviewed figures above. Not a ranking or recommendation.